Outcome of combined interferon-ribavirin in the treatment of chronic hepatitis C

Journal of the College of Physicians and Surgeons Pakistan

Volumn 14, Issue 11, 2004, Pages 651-653

  Muhammad, Noor ^a,b   Jan, M Ayub ^a   Rahman, Noor ^a  

^a DHQ Hospital Daggar   (Pakistan)

^b NONE   (Pakistan)

Author keywords

Chronic hepatitis C; Interferon; Ribavirin; Virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; HEPATITIS C ANTIBODY; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANXIETY DISORDER; ARTICLE; BIOCHEMISTRY; BLOOD TOXICITY; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG TOLERABILITY; DRY SKIN; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL DEPARTMENT; HUMAN; INSOMNIA; LEUKOPENIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MENTAL INSTABILITY; MYOPATHY; NONHUMAN; PAKISTAN; POLYMERASE CHAIN REACTION; PRURITUS; RETINOPATHY; SKIN DISEASE; SUICIDE ATTEMPT; THROMBOCYTOPENIA; THYROTOXICOSIS; TREATMENT OUTCOME; VIRUS DETECTION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 11844251163     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. National Institute of Health Consensus statement; management of hepatitis C. Hepatology 2002; 36(supple I):51-20.
2. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88: 240-3.
3. Chen DS. Hepatitis B and C virus infections in hepatocellular carcinoma and their prevention. In: Nishioka K, Suzuki H, Mishiro S, Oda T, (edi). Viral hepatitis and liver disease . Tokyo: Springer Verlag 1994; 685-9.
4. Alter MJ. Epidermiology of hepatitis C. Hepatology 1997; 26 (suppl 1): 625-55.
5. Terrault NA, Wright TI. Hepatitis C virus in the setting of transplantations. Semin Liver Dis 1995; 15: 92-100.
6. Hoofnagle JH, Mullen KD, Jones BD, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: preliminary report. N Engl J Med 1986, 315:1575-8.
7. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15: 82-91.
8. Tine F, Margin S, Craxi A, Pagllaro L. Interferon for non-A, non-B chronic hepatitis. A meta analysis of randomized clinical trials. J Hepatol 1991; 13:192-9.
9. Saracco G, Risina F, Abate ML, Chiandussi L, Gallo V, Cerutt E, et al. Long term follow-up of patients with chronic hepatitis C treated with different doses of interferon alpha-2b. Hepatology 1993; 18: 1300-5.
10. Marcellin P, Boyer N, Degott C, Martinot-Peignoux M, Duchatella V, Giostra E, et al. Long-term histological and viral changes its patients with chronic hepatitis C, who responded to alpha interferon. Hepatology 1994; 14: 302-7.
11. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alpha-2b trials. Hepatology 1997; 26 (3 suppl): 83S-8s.
12. Poynard T, Bedossa P, Chevallier M, Matturin P, Lemonnier C, Trepo C, et al. A comparison of three Interferon alpha-2b regimens for long-terms treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332:1457-62.
13. Di Bisceglie AM, Shindo M, Frong TL, Fried MW, Swain MG, Bergasa NV, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-54.
14. Fernandez H, Banks G, Smith R. Ribavirin: a clinical overview. Eur J Epidermal 1986; 2:1-14.
15. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337:1058-61.
16. Reichard O. Norkrans G, Fryden A, Brachonier JH, Sonnerborg A, Weiland O. Randomized double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351:83-7.
17. Selivarez R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with previously non-response or non-sustained response to interferon alone. J Med Virol 1995; 46: 43-7.
18. Mc Hutchinsum JG, Straut C, Gordan, Eugene RS, Mitchell L. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
19. Giuseppe B, Gabriella DL, Maurizio S, Giuseppe G, Giorgio B, Giancarlo E, et al. Interferon-2b and ribavirin in combination for chronic hepatitis C. Patients not responding to interferon alpha alone. An Italian multicenter, randomized, controlled clinical trial. Am J Gastroenterol 1998; 39: 2445-51.
20. Patterson JL, Fernandez-Larsson R. Molecular mechanism of action of ribavirin. Rev Infect Disease 1990; 12:1132-46.
21. Bodenheiner HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473-7.
22. Hayden FC, Schlepushkin AN, Pushkarskaya NL. Combined interferon alpha-2, amantadin hydrochloride and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother 1984; 25: 53-7.
23. Tang MJ, Blatt IM, Mc Hutchinson JG, Co RL, Conrod A. Prediction of response during interferon alpha-2b therapy in chronic hepatitis C patients using viral bio-chemicals: a comparison. Hepatology 1997; 26: 1640-5.
24. Mc Hutchinson J, Blatt L, Sedghi VA, Ressell J, Schmid P, Conrad A. Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection? J Hepatol 1998; 29: 362-8.
25. Poynard T, Marcelein P, Lee SS, Niederau C, Minuk GS, Ideo G. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus. International Hepatitis Interventional therapy. Lancet 1998; 352: 1426-32.
26. Ming YL, Jia HK, Pei MY, Jin TW, Pei JC, Kin WC, et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-12.
27. Farooqi JI, Farooqi RJ, Khalid H. Interferon, 2b-mono therapy and in combination with ribavirin as initial treatment for chronic hepatitis C. J Coll Physicians Surg Pak 2002; 12: 82-5.
28. Wazir MS, Majid AS, Solangi GA, Zuberi BF. Role of interferon and interferon plus ribavirin in the management of chronic hepatitis C. J Coll Physicians Surg Pak 2002; 12:609-12.
29. Shafi MS, Ahmed SI, Rehan M, Gulam Mustafa. Daily interferon versus interferon thrice weekly in combination with ribavirin for treatment of chronic hepatitis C. J Rawalpindi Med Coll 1999; 31 20-2.
30. Idrees M. Common genotypes of hepatitis C virus present in Pakistan. Pak J Med Res 2001; 40: 46-9.
31. Idrees M. Comparison of two typing systems for genotyping of hepatitis C virus isolates. J Coll Physicians Surg Pak 2000; 11 22-5.
32. Idrees M. Detection of six serotypes of HCV in anti-HCV positive patients and rate of ALT/AST abnormalities. Pak J Microbiol 2001; 2: 61-5.
33. Stuyver LJ, Mc Brayer TR, Tharmish PM, Hassan AE, Chu CK, Pankiewiez KW, et al. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J Virol 2003; 77: 10689-94.